Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.66 |
| ▸ | HPGD | P15428 | 3/20 | 0.66 |
| ▸ | POLB | P06746 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15134834 | 0.88 | POLB (0.68) | POLBALDH1A1LMNASMN1; SMN2TDP1 | |
| SCHEMBL335195 | 0.87 | FKBP1A (0.74) | RAB9AHPGDPOLBMAPTALDH1A1 | |
| SCHEMBL653789 | 0.87 | TPSAB1 (0.72) | RAB9AHPGDPOLBMAPTALDH1A1 | |
| SCHEMBL2829286 | 0.87 | ACHE (0.69) | POLBMAPTALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL16661998 | 0.85 | POLB (0.60) | POLBMAPTALDH1A1LMNASMN1; SMN2 | |
| Pifoxime SCHEMBL29849546 | 0.84 | RAB9A (0.62) | RAB9AHPGDPOLBMAPTALDH1A1 | |
| Pifoxime SCHEMBL26342 | 0.84 | RAB9A (0.62) | RAB9AHPGDPOLBMAPTALDH1A1 | |
| SCHEMBL10244937 | 0.84 | NPC1 (0.57) | POLBMAPTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL4384355 | 0.84 | KDM4E (0.70) | POLBMAPTALDH1A1LMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4377279 | 0.83 | KDM4E (0.68) | POLBMAPTALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-1985620-A1 | 10a-AZALIDE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2008-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | RAB9A 5/4885HPGD 556/4885POLB 3348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.